The use of different antibodies, sample sizes, patient populations, scoring methods, and brain tumour cells of various origins and tumour heterogeneity may have been some of the factors contributing to the conflicting data on the expression level of EGFR expression and their prognostic significance in patients with brain tumour. The gene discussed is EGFR; the disease is brain neoplasm.